# ZL-1310

Source: https://onco.cc/drugs/zl-1310/  
OnCo record `zl-1310` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.

## Summary

ZL-1310 is an antibody-drug conjugate developed by Zai Lab (Shanghai). Its target is DLL3 (the sponsor names DLL3). The sponsor states: ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07218146 (A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)), in non-small-cell lung cancer. The largest, NCT07218146, plans to enrol 480 participants with primary completion expected 2028-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: ZL-1310 is a DLL3-targeting antibody-drug conjugate (ADC), given as a single agent versus investigator's choice therapy (topotecan or amrubicin) in relapsed small cell lung cancer.

## Notes

- 23 Sept 2026: the payload is not stated on any record OnCo reads, so the open drug engine shows ZL-1310 under DLL3 with the payload class not recorded rather than guessing.

## Sources

- ClinicalTrials.gov: trials of ZL-1310: https://clinicaltrials.gov/search?intr=ZL-1310

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)
- trials: [A Study of ZL-1310 in Participants With Selected Solid Tumors](https://onco.cc/trials/nct06885281/), [A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)](https://onco.cc/trials/dllevate/), [DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers](https://onco.cc/trials/nct07707895/)

---
JSON: https://onco.cc/api/v1/entities/zl-1310.json